California-based Affymax, Inc. has received a $10-million milestone payment from Japan-based Takeda Pharmaceutical Co. to develop and market peginesatide, an investigational drug for the treatment of anemia in chronic renal-failure patients. The news comes after the Food and Drug Administration accepted Affymax’s new drug application for peginesatide, formerly known as Hematide ™. If approved, the companies plan to market the drug in the United States, with Takeda commercializing the drug in other countries. See Affymax® Press Release, August 10, 2011.